ArticleProceedings (Baylor University. Medical Center)
Real-world evidence of the impact of aspirin use on esophageal cancer incidence in Barrett's esophagus patients.
Article in Proceedings (Baylor University. Medical Center). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Barrett's esophagus (BE) is the main precursor to esophageal adenocarcinoma, a cancer with a significantly rising incidence. While proton-pump inhibitors (PPIs) are the standard therapy for managing BE, the chemopreventive role of aspirin is an area of growing interest with inconclusive evidence, particularly regarding its use in combination with PPIs. This study aimed to assess whether adding aspirin to PPI therapy reduces the incidence of esophageal cancer in patients with BE more than PPIs alone. Methods: A nationwide retrospective cohort study was conducted using the TriNetX database. Adult patients with BE were divided into two cohorts: those receiving aspirin plus a PPI and those receiving a PPI only. Propensity score matching was used to balance baseline demographics and clinical comorbidities. The primary outcome was the incidence of malignant neoplasm of the lower third of the esophagus. Subgroup analyses were also performed for low-dose (81 mg) and high-dose (300-325 mg) aspirin. Results: After matching, each cohort included 88,184 patients. The cohort receiving aspirin and PPIs had a lower risk of developing esophageal cancer compared to the PPI-only cohort (odds ratio [OR] 0.799, 95% CI: 0.679-0.941). The protective association was observed in both high-dose (OR 0.643) and low-dose (OR 0.664) aspirin subgroups, suggesting a potential dose-dependent effect. Conclusion: This large, real-world analysis suggests that the concurrent use of aspirin with PPIs is associated with a reduced risk of esophageal cancer in patients with BE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.